CLARITY 2 - Depression Research Study: Adjunctive Treatment of Major Depressive Disorder

  • STATUS
    Not Recruiting
  • days left to enroll
    9
Updated on 12 January 2021

Summary

Summit Research Network is enrolling participants in an investigational medication research study for Major Depressive Disorder.  The purpose of this study is to  evaluate the efficacy and safety of adjunctive pimavanserin compared to placebo in subjects with major depressive disorder who have  inadequate response to antidepressant therapy. 

Qualified participants may be involved for up to 14 weeks and visit the research center 8 times.  At the first visit, qualified participants will enter a screening period. After the initial screening period participants will receive either the investigational medication or a placebo (an inactive substance) for up to 6 weeks and visit the research center weekly.  Thirty days after the last dose of theinvestigational medication, participants will complete a follow-up visit by phone.

 

Description

Study-related psychological evaluation, physical exam, laboratory tests and ECG are provided to the research study participants at designated visits throughout the study. As with all studies at Summit, if you qualify for this research study all research related care, study medication and office visits will be provided at no cost.

Details
Condition Depression, Depression (Major/Severe), Depression (Adolescent), Depression (Pediatric), Depression (Adult and Geriatric), Depression (Treatment-Resistant)
Clinical Study IdentifierTX224556
Last Modified on12 January 2021

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note